Delta-like canonical Notch ligand 3 (DLL3) has attracted recent attention as a molecule that is highly expressed in SCLC, and as a therapeutic target of antibody–drug conjugate rovalpituzumab tesirine (ROVA-T). The gene discussed is DLL3; the disease is small cell lung carcinoma.